Ted Kellner Issues Letter to AIM ImmunoTech (AIM)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
AIM’s Clinical Strategy Under Incumbent Board Has Totally Failed
December 11, 2024 7:30 AM ESTIncumbent Boards Claims of Progress Are Not Credible or Supported by Data
AIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Investors about the Timeline and Status of Regulatory Submissions to the U.S. FDA
According to ISS The lack of transparency gives the impression that the companys pipeline is more advanced and that the company is more involved than it actually is1
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with... More
